Literature DB >> 16091260

Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients.

Obiamiwe C Umeh1, Judith S Currier.   

Abstract

The availability of potent combination antiretroviral therapy has changed the long-term prognosis for people living with HIV/AIDS. There is increasing concern, however, about the effect of HIV therapy on lipid disorders and subsequent development of coronary artery disease. Virtually all classes of antiretroviral drugs have been associated with some aspect of atherogenic changes in the lipid profiles. This article reviews the current literature on HIV-associated dyslipidemias and the metabolic syndrome, their potential effect on future coronary heart disease, and reviews strategies for management.

Entities:  

Mesh：

Year:  2005        PMID： 16091260     DOI： 10.1007/s11904-005-0006-6

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN： 1548-3568            Impact factor:   5.071


  49 in total

1.  Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors.

Authors:  Carlos Jericó; Hernando Knobel; Milagro Montero; Jordi Ordoñez-Llanos; Ana Guelar; Juan L Gimeno; Pere Saballs; Jose L López-Colomés; Juan Pedro-Botet
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

2.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

Review 3.  Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

Authors:  Pedro E Cahn; José M Gatell; Kathleen Squires; Lisa D Percival; Peter J Piliero; Ian A Sanne; Sarah Shelton; Adriano Lazzarin; Linda Odeshoo; Thomas D Kelleher; Alexandra Thiry; Michael D Giordano; Stephen M Schnittman
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2004 Jul-Sep

4.  Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.

Authors:  Leonardo Calza; Roberto Manfredi; Barbara Farneti; Francesco Chiodo
Journal:  Int J Antimicrob Agents       Date:  2003-07       Impact factor: 5.283

5.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

6.  Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.

Authors:  John K Ninomiya; Gilbert L'Italien; Michael H Criqui; Joanna L Whyte; Anthony Gamst; Roland S Chen
Journal:  Circulation       Date:  2003-12-15       Impact factor: 29.690

7.  HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.

Authors:  Barry E Hurwitz; Nancy G Klimas; Maria M Llabre; Kevin J Maher; Jay S Skyler; Martin S Bilsker; Shvawn McPherson-Baker; Peter J Lawrence; Arthur R Laperriere; Jeffrey M Greeson; Johanna R Klaus; Rasha Lawrence; Neil Schneiderman
Journal:  Cardiovasc Toxicol       Date:  2004       Impact factor: 3.231

8.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

9.  A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

Authors:  Cesar Fisac; Nuria Virgili; Elena Ferrer; Maria J Barbera; Emilio Fumero; Concepcio Vilarasau; Daniel Podzamczer
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

Authors:  Philip H Keiser; Michael G Sension; Edwin DeJesus; Allan Rodriguez; Jeffrey F Olliffe; Vanessa C Williams; John H Wakeford; Jerry W Snidow; Anne D Shachoy-Clark; Julie W Fleming; Gary E Pakes; Jaime E Hernandez
Journal:  BMC Infect Dis       Date:  2005-01-12       Impact factor: 3.090
View more
  6 in total

Review 1.  Economic models of antiretroviral therapy: searching for the optimal strategy.

Authors:  Fred J Hellinger
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy.

Authors:  C Kahlert; A Bregenzer; C Gutmann; S Otterbech; M Hoffmann; P Schmid; P Vernazza
Journal:  Infection       Date:  2015-12-11       Impact factor: 3.553

3.  Long-term safety from the raltegravir clinical development program.

Authors:  Hedy Teppler; Deborah D Brown; Randi Y Leavitt; Peter Sklar; Hong Wan; Xia Xu; Fabio Lievano; Heidi P Lehman; T Christopher Mast; Bach-Yen T Nguyen
Journal:  Curr HIV Res       Date:  2011-01       Impact factor: 1.581

4.  Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.

Authors:  Anna M Grandi; Eleonora Nicolini; Laura Rizzi; Sara Caputo; Filippo Annoni; Anna M Cremona; Chiara Marchesi; Luigina Guasti; Andrea M Maresca; Paolo Grossi
Journal:  J Int AIDS Soc       Date:  2014-08-21       Impact factor: 5.396

5.  Expression of the inflammasome components and its relationship with cardiovascular risk markers in people living with HIV-1

Authors:  Kevin León; Damariz Marín-Palma; Salomón Gallego; Crisitina Yepes; Jhonatan Vélez; Gustavo A Castro; Fabián Jaimes; Natalia Taborda; María Teresa Rugeles; Juan C Hernández
Journal:  Biomedica       Date:  2022-06-01       Impact factor: 1.173

6.  Dyslipidaemia and Intima-Media Thickness of Carotid Arteries in Thirty-Five HIV/AIDS Patients Receiving Highly Active Antiretroviral Therapy.

Authors:  Xuexiang Zhang; Xueyan Jiang; Hongzhou Lu; Fang Shen; Jiangrong Wang
Journal:  Int J Biomed Sci       Date:  2009-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.